Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
‘Better drugs that are affordable and accessible to many more people.’
Significant in bringing any drug to market.
Cost v life extension/quality of life.
AS is very passionate about this concept.
RAH
Your thoughts/opinions are certainly welcome.
Many thanks for your informative posts; pls continue.
Delayed trades…
Robbie
We're delighted with the very positive data emerging from the dose escalation study of our lead pre|CISIONTM tumour targeted therapy AVA6000. The very significant reduction in the usual toxicities, plus the observed release of doxorubicin at significant levels in the tumour tissue, show that the pre|CISIONTM platform has the potential to significantly improve the safety and tolerability of chemotherapies, and other drugs, by targeting their release to the tumour.
"This is extremely encouraging as we work towards realising our vision of "chemotherapy without side effects" to make a meaningful difference to cancer patients' lives.
"We are now in a position to proceed beyond the fourth cohort in the dose escalation study to even higher doses than originally anticipated, which is an unexpected and very positive development. The data being generated in the ALS-6000-101 study are providing detailed insights into the pre|CISIONTM platform which add significant value to the technology and confirm the potential of the pre|CISIONTM platform."
Why ask people on here?
Listen to the main man.
Richar
What are you expecting?
Maybe he might send you an email this evening.
The discussion that has taken place today will be available tomorrow!!
What should AS have said?
We haven’t any news since the incredible RNS from mid-Jan and these groundbreaking trials can be fully completed in two weeks?
Some right lunatics on here spreading crap.
Oak
I wasn’t aware I was giving you any advice.
Pls re-read, as I was speaking to another poster with a tongue-in-cheek comment.
Take it easy with the abuse, as I don’t work in the circus.
Oak
Don’t wish someone that has sold half their shares ‘good luck’.
I wish all LTHs ‘good luck’.
Just saying…
I tried to sell my mill but then changed my mind…
…..
Trying to rinse out the weak, from what I see hurst?
GMCC
Thanks for your posts.
To do this day I was away skiing, and was hoping to receive the amazing topline results of the Interferon P3 trial Synairgen ran to treat Covid 19.
Unfortunately, the news was disastrous as it failed to meet primary and secondary endpoints resulting in massive losses for investors.
Thankfully, Avacta came to the rescue for me and have enabled me to recover most of the losses I suffered.
One year on, as I’m skiing in the same place at the same time I’ve got everything crossed that Science day will bring us all some good fortune and increase the SP even more. Not forgetting, of course, the many cancer sufferers that may get life saving treatment, too.
GLA
Up to 174, down to 168/9 by the end of the day.
Just saying, predictability from the MMs.
Do is a favour….
It’s like a caged lion, MMs definitely struggling to hold this back.
Depends if you’re an optimist or a pessimist.
I’m the former :)
And of course if there’s any negative slant whatsoever, you’ll be all over it like a little school child won’t you Viking.
Because, you’re not invested but still spend your time on this board.
What a moby….
Then leave WYN.
Why are you still invested?
Obviously you aren’t invested.
Spending time on boards you aren’t invested in? Bit strange?
Touk
How did AS respond to your analytical discussion last night? Did he accept your advice? What did you tell him the next steps were?
Except you didn’t as you’re a nobody.
HE is the expert, not you. Listen to the experts!!
What a moby…..
Riesgo
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Additionally, analysis of tumour biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumour tissue confirming the tumour targeting potential of the pre|CISIONTM technology.
AVA6000 continues to be well tolerated by patients in cohort 4 with a marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration. Typical toxicities include alopecia, myelosuppression, nausea, vomiting, mucositis and cardiotoxicity. Importantly, even at the highest dosing levels in cohort 4, equivalent to more than double the normal dose of doxorubicin, the typical drug-related cardiotoxicity of doxorubicin was not observed.
A number of tumour biopsies obtained from patients in different cohorts have also been analysed in order to confirm the release of the active chemotherapy, doxorubicin, in the tumour tissue. This analysis shows that AVA6000 targets the release of doxorubicin to the tumour tissue at therapeutic levels which are much higher than the levels being detected in the bloodstream at the same timepoint.
Viking
I see they’ve had enough of you on the SYM board.
A little tip, so have we.